Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqGM:VCYT
High Growth Tech Stocks To Watch In November 2024
Reviewed by Simply Wall St
In the last week, the United States market has stayed flat; however, it is up 33% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that can capitalize on strong earnings potential and sustain momentum in a rapidly evolving sector.
Top 10 High Growth Tech Companies In The United States
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Sarepta Therapeutics | 23.89% | 42.65% | ★★★★★★ |
Invivyd | 47.87% | 67.72% | ★★★★★★ |
TG Therapeutics | 34.66% | 56.48% | ★★★★★★ |
Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.45% | 70.66% | ★★★★★★ |
Blueprint Medicines | 25.26% | 68.92% | ★★★★★★ |
Travere Therapeutics | 31.19% | 72.58% | ★★★★★★ |
Cloudflare | 20.51% | 23.80% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 246 stocks from our US High Growth Tech and AI Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
MongoDB (NasdaqGM:MDB)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MongoDB, Inc., along with its subsidiaries, offers a general-purpose database platform globally and has a market capitalization of approximately $21.54 billion.
Operations: The company generates revenue primarily from its data processing segment, amounting to $1.82 billion.
MongoDB, a key figure in the tech industry, is navigating through unprofitable waters with a net loss of $54.53 million in Q2 2024, widening from the previous year. Despite these challenges, it forecasts robust annual revenue growth at 15.4%, outpacing the US market's 9%. The company's commitment to innovation is evident in its R&D spending which has been strategically aligned with its growth trajectory; however, specific figures were not disclosed. Recent integrations like MongoDB Atlas-PowerSync highlight its focus on enhancing data synchronization technologies for developers, ensuring MongoDB remains at the forefront of database solutions and cloud services. This strategic direction not only addresses immediate application performance needs but also sets the stage for future profitability and sustained growth in an increasingly digital economy.
- Click here to discover the nuances of MongoDB with our detailed analytical health report.
Review our historical performance report to gain insights into MongoDB's's past performance.
Veracyte (NasdaqGM:VCYT)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Veracyte, Inc. is a diagnostics company that operates both in the United States and internationally, with a market capitalization of approximately $2.96 billion.
Operations: Veracyte generates revenue primarily through its diagnostic products, amounting to $425.33 million.
Veracyte has demonstrated a notable turnaround, with its recent quarterly earnings revealing net income of $15.16 million, contrasting sharply with a net loss of $29.62 million in the same period last year. This financial rebound is underscored by a significant revenue increase to $115.86 million from $90.11 million, reflecting a growth rate of 28%. The company's commitment to innovation is evident in its R&D investments, aligning closely with its strategic priorities and market demands; however, specific R&D expenditure figures were not disclosed. Additionally, Veracyte's raised full-year revenue guidance to between $442 million and $445 million indicates confidence in continued growth and market penetration, especially within its genomic testing segments which play a crucial role in advancing personalized medicine for complex diseases like prostate cancer.
- Click to explore a detailed breakdown of our findings in Veracyte's health report.
Gain insights into Veracyte's past trends and performance with our Past report.
Sea (NYSE:SE)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Sea Limited operates in digital entertainment, e-commerce, and digital financial services across Southeast Asia, Latin America, the rest of Asia, and internationally with a market capitalization of $61.83 billion.
Operations: Sea Limited generates revenue primarily through its digital entertainment, e-commerce, and digital financial services businesses. The company operates in diverse regions including Southeast Asia and Latin America. It leverages its extensive market presence to cater to a wide range of consumer needs across these sectors.
Sea Limited has pivoted impressively this year, turning a net loss into a substantial net income of $153.32 million in Q3 2024, up from a loss the previous year, with revenue surging to $4.33 billion from $3.31 billion. This growth is underpinned by an aggressive R&D strategy that aligns with its broader market ambitions; notably, R&D expenses have been meticulously managed to fuel innovations essential for staying competitive in the tech arena. The company's earnings are expected to grow by 46.2% annually, outpacing the US market's average growth rate significantly and reflecting strong operational execution despite past volatility marked by one-off losses totaling $196.9 million last fiscal year.
- Unlock comprehensive insights into our analysis of Sea stock in this health report.
Gain insights into Sea's historical performance by reviewing our past performance report.
Seize The Opportunity
- Embark on your investment journey to our 246 US High Growth Tech and AI Stocks selection here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:VCYT
Veracyte
Operates as a diagnostics company in the United States and internationally.